hydroxychloroquine has been researched along with Respiratory Distress Syndrome, Newborn in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Respiratory Distress Syndrome, Newborn: A condition of the newborn marked by DYSPNEA with CYANOSIS, heralded by such prodromal signs as dilatation of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, mostly frequently occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and sometimes with no apparent predisposing cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Several management options for prolongation of pregnancy such as plasma exchange, pravastatin, LMHW, hydroxychloroquine/HCQ, or TNF-alpha blocker should be discussed with the patients." | 3.96 | Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. ( Cervar-Zivkovic, M; Mayer-Pickel, K; Moertl, M; Schöll, W; Stern, C, 2020) |
| "The girl developed interstitial lung disease." | 2.50 | Neonatal respiratory insufficiency caused by an (homozygous) ABCA3-stop mutation: a systematic evaluation of therapeutic options. ( Aslanidis, C; Bartsch, M; Essmann, S; Griese, M; Kidszun, A; Mildenberger, E; Poplawska, K; Schmitz, G; Winter, J, 2014) |
| "Here, we report a 20-month-old boy with interstitial lung disease caused by two distinct ABCA3 mutations." | 1.39 | Interstitial lung disease in two brothers with novel compound heterozygous ABCA3 mutations. ( Kawano, K; Kitazawa, H; Kure, S; Moriya, K; Niizuma, H; Rikiishi, T; Saito-Nanjo, Y; Sakamoto, O; Sasahara, Y; Setoguchi, Y; Uchiyama, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Mayer-Pickel, K | 1 |
| Stern, C | 1 |
| Cervar-Zivkovic, M | 1 |
| Schöll, W | 1 |
| Moertl, M | 1 |
| Shaaban, W | 1 |
| Hammoud, M | 1 |
| Abdulraheem, A | 1 |
| Elsayed, YY | 1 |
| Alkazemi, N | 1 |
| Mitsiakos, G | 1 |
| Tsakalidis, C | 1 |
| Karagianni, P | 1 |
| Gialamprinou, D | 1 |
| Chatziioannidis, I | 1 |
| Papoulidis, I | 1 |
| Tsanakas, I | 1 |
| Soubasi, V | 1 |
| Kitazawa, H | 1 |
| Moriya, K | 1 |
| Niizuma, H | 1 |
| Kawano, K | 1 |
| Saito-Nanjo, Y | 1 |
| Uchiyama, T | 1 |
| Rikiishi, T | 1 |
| Sasahara, Y | 1 |
| Sakamoto, O | 1 |
| Setoguchi, Y | 1 |
| Kure, S | 1 |
| Hepping, N | 1 |
| Griese, M | 2 |
| Lohse, P | 1 |
| Garbe, W | 1 |
| Lange, L | 1 |
| Winter, J | 1 |
| Essmann, S | 1 |
| Kidszun, A | 1 |
| Aslanidis, C | 1 |
| Poplawska, K | 1 |
| Bartsch, M | 1 |
| Schmitz, G | 1 |
| Mildenberger, E | 1 |
| Hayes, D | 1 |
| Lloyd, EA | 1 |
| Fitch, JA | 1 |
| Bush, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine in Pediatric ILD With Genetic Surfactant Dysfunction Disorders: Cross-control, Prospective Study[NCT03822780] | 25 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Respiratory Distress Syndrome, Newborn
| Article | Year |
|---|---|
Neonatal respiratory insufficiency caused by an (homozygous) ABCA3-stop mutation: a systematic evaluation of therapeutic options.
Topics: Adrenal Cortex Hormones; ATP-Binding Cassette Transporters; Chromosome Aberrations; Codon, Terminato | 2014 |
6 other studies available for hydroxychloroquine and Respiratory Distress Syndrome, Newborn
| Article | Year |
|---|---|
Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases.
Topics: Adult; Antiphospholipid Syndrome; Female; Fetal Viability; Gestational Age; Heparin, Low-Molecular-W | 2020 |
Hydroxychloroquine, a successful treatment for lung disease in ABCA3 deficiency gene mutation: a case report.
Topics: ATP-Binding Cassette Transporters; Child; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Lung | 2021 |
A New
Topics: Adrenal Cortex Hormones; ATP-Binding Cassette Transporters; Azithromycin; Humans; Hydroxychloroquine | 2019 |
Interstitial lung disease in two brothers with novel compound heterozygous ABCA3 mutations.
Topics: ATP-Binding Cassette Transporters; Fatal Outcome; Heterozygote; Humans; Hydroxychloroquine; Infant; | 2013 |
Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p.Cys121Gly mutation with hydroxychloroquine.
Topics: Amino Acid Substitution; Cesarean Section; Cysteine; DNA Mutational Analysis; Exons; Female; Follow- | 2013 |
ABCA3 transporter deficiency.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; ATP-Binding Cassette Transporters; Azithromycin; Dr | 2012 |